Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations

Journal of Cystic Fibrosis

Volumn 13, Issue 1, 2014, Pages 15-23

  Sommerburg, Olaf ^a,b   Krulisova, Veronika ^c   Hammermann, Jutta ^d   Lindner, Martin ^a   Stahl, Mirjam ^a,b   Muckenthaler, Martina ^a,b   Kohlmueller, Dirk ^a   Happich, Margit ^a   Kulozik, Andreas E ^a   Votava, Felix ^e   Balascakova, Miroslava ^c   Skalicka, Veronika ^c   Stopsack, Marina ^d   Gahr, Manfred ^d   Macek, Milan ^c   Mall, Marcus A ^a,b,f   Hoffmann, Georg F ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b German Center for Lung Research (DZL)   (Germany)

^c UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e CHARLES UNIVERSITY   (Czech Republic)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Biochemical screening; Cystic fibrosis; Immunoreactive trypsinogen; Newborn screening; Pancreatitis associated protein

Indexed keywords

IMMUNOREACTIVE TRYPSINOGEN; PANCREATITIS ASSOCIATED PROTEIN; TRYPSINOGEN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL EVALUATION; CLINICAL PROTOCOL; CONTROLLED STUDY; CYSTIC FIBROSIS; CZECH REPUBLIC; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; EUROPE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEWBORN; NEWBORN SCREENING; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; SWEAT TEST; TREND STUDY;

BIOCHEMICAL SCREENING; CF; CFNBS; CYSTIC FIBROSIS; CYSTIC FIBROSIS NEWBORN SCREENING; DBS; DRIED BLOT SPOT; FAILSAFE STRATEGY; FS; IMMUNOREACTIVE TRYPSINOGEN; IRT; MECONIUM ILEUS; MI; NBS; NEWBORN SCREENING; PANCREATIC INSUFFICIENT; PANCREATIC SUFFICIENT; PANCREATITIS ASSOCIATED PROTEIN; PAP; PI; PS;

ANTIGENS, NEOPLASM; CHEMISTRY, CLINICAL; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRIED BLOOD SPOT TESTING; EUROPE; GENETIC TESTING; HUMANS; INFANT, NEWBORN; LECTINS, C-TYPE; NEONATAL SCREENING; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TRYPSINOGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84890441466     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2013.06.003     Document Type: Article

References (21)

1. Farrell P.M., Lai H.J., Li Z., Kosorok M.R., Laxova A., Green C.G., et al. Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough!. J Pediatr 2005, 147:S30-S36.
2. Comeau A.M., Accurso F.J., White T.B., Campbell P.W., Hoffman G., Parad R.B., et al. Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. Pediatrics 2007, 119:e495-e518.
3. Castellani C., Southern K.W., Brownlee K., Dankert Roelse J., Duff A., Farrell M., et al. European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros 2009, 8:153-173.
4. Wilcken B., Wiley V. Newborn screening methods for cystic fibrosis. Paediatr Respir Rev 2003, 4:272-277.
5. Munck A., Dhondt J.L., Sahler C., Roussey M. Implementation of the French nationwide cystic fibrosis newborn screening program. J Pediatr 2008, 153:228-233.
6. Ross L.F. Newborn screening for cystic fibrosis: a lesson in public health disparities. J Pediatr 2008, 153:308-313.
7. Sarles J., Berthezene P., Le Louarn C., Somma C., Perini J.M., Catheline M., et al. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis. J Pediatr 2005, 147:302-305.
8. Sommerburg O., Lindner M., Muckenthaler M., Kohlmueller D., Leible S., Feneberg R., et al. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population. J Inherit Metab Dis 2010, 33:S263-S271.
9. Vernooij-van Langen A.M., Loeber J.G., Elvers B., Triepels R.H., Gille J.J., Van der Ploeg C.P., et al. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study. Thorax 2012, 67:289-295.
10. Krulišová V., Balaščaková M., Skalická V., Piskáčková T., Holubová A., Paděrová J., et al. Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA. Eur J Pediatr 2012, 171:1223-1229.
11. Hammermann J., Mense L., Stopsack M. Newborn screening for cystic fibrosis with an IRT-PAP protocol. J Cyst Fibros 2012, 11:S47. [Abstract].
12. Gibson L.E., Cooke R.E. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959, 23:545-549.
13. Green A., Kirk J. Guidelines for the performance of the sweat test for the diagnosis of cystic fibrosis. Ann Clin Biochem 2007, 44:25-34.
14. - channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterology 2004, 127:1085-1095.
15. Mall M., Kreda S.M., Mengos A., Jensen T.J., Hirtz S., Seydewitz H.H., et al. The {increment}F508 mutation results in loss of CFTR function and mature protein in native human colon. Gastroenterology 2004, 126:32-41.
16. Hentschel J., Riesener G., Nelle H., Stuhrmann M., Schöner A., Sommerburg O., et al. Homozygous CFTR mutation M348K in a boy with respiratory symptoms and failure to thrive. Disease-causing mutation or benign alteration?. Eur J Pediatr 2012, 171:1039-1046.
17. Mayell S.J., Munck A., Craig J.V., Sermet I., Brownlee K.G., Schwarz M.J., et al. A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis. J Cyst Fibros 2009, 8:71-78.
18. Stock C., Hielscher T. DTComPair: comparison of binary diagnostic tests in a paired study design. R package version 1.00 2013, [Internet Communication].
19. Comeau A.M., Parad R.B., Dorkin H.L., Dovey M., Gerstle R., Haver K., et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics 2004, 113:1573-1581.
20. Sontag M.K., Wright D., Beebe J., Accurso F.J., Sagel S.D. A new cystic fibrosis newborn screening algorithm: IRT/IRT1 upward arrow/DNA. J Pediatr 2009, 155:618-622.
21. Vernooij-van Langen A.M., Loeber J.G., Elvers B., Triepels R.H., Roefs J., Gille J.J., et al. The influence of sex, gestational age, birth weight, blood transfusion, and timing of the heel prick on the pancreatitis-associated protein concentration in newborn screening for cystic fibrosis. J Inherit Metab Dis 2013, 36:147-154.